Markets
Revelation Biosciences, Inc. (REVB)
REVBNASDAQ-CMBiotechnology: Pharmaceutical Preparations
$4.12
+0.1800 (+4.57%) today
Closed, Nov 9, 4:00 PM ET
+4.57% 1D
- Market cap
- $2.78m
- P/E
- –
- EPS, last 4 quarters
- $-42.52
- Dividend yield
- –
- Day range
- –
- 52-week range
- $3.08 to $40.60
- Average volume
- 13.2k
- Previous close
- $3.94
Earnings
next estimate $-5.98Next report
Dec 2025
-17.0%
Mar 2026
-135.5%
Jun 2026
-4.8%
Sep 2026
+3.9%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$1.94m | -$2.57m | -$3.09m | -$3.66m |
| Net income | -$1.91m | -$2.51m | -$3.01m | -$3.32m |
News
1 latestThe company
Revelation Biosciences, Inc. is a clinical-stage life sciences company focused on rebalancing inflammation using its proprietary formulation, Gemini. Revelation has multiple ongoing programs to evaluate Gemini as a treatment for acute kidney injury, a treatment for chronic kidney disease, prevention of post-surgical infection, and a treatment to reduce hyperinflammation and infection associated with severe burn.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- revbiosciences.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.